Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$31 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-12 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
-1.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-6918.4
Face value
--
Shares outstanding
58,283,600
CFO
$-66.49 Mln
EBITDA
$-172.60 Mln
Net Profit
$-193.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Enochian Biosciences (ENOB)
| 51.5 | 201.2 | 30.0 | -42.0 | -28.7 | -17.2 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Enochian Biosciences (ENOB)
| -85.9 | 147.1 | -41.2 | -28.3 | 47.1 | 216.7 | -61.5 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Enochian Biosciences (ENOB)
|
1.6 | 31.0 | 0.0 | -387,426.8 | -- | -567853.8 | -- | 0.4 |
| 106.9 | 9,085.1 | 167.7 | -63.1 | -24.9 | -26.1 | -- | 33.0 |
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and... cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California. Read more
CEO, Director & Member of HBV Scientific Advisory Board
Dr. Mark R. Dybul M.D.
CFO & Corp. Sec.
Ms. Luisa Puche
Headquarters
Los Angeles, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Enochian Biosciences Inc (ENOB) is $1.56 (NASDAQ) as of 11-Aug-2023 09:30 EDT. Enochian Biosciences Inc (ENOB) has given a return of -28.68% in the last 3 years.
Since, TTM earnings of Enochian Biosciences Inc (ENOB) is negative, P/E ratio is not available.
The P/B ratio of Enochian Biosciences Inc (ENOB) is 0.45 times as on 23-Jun-2023, a 89 discount to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.90
|
1.41
|
|
2021
|
-8.74
|
1.34
|
|
2020
|
-17.84
|
1.16
|
|
2019
|
-6.81
|
0.99
|
|
2018
|
-7.98
|
0.47
|
The 52-week high and low of Enochian Biosciences Inc (ENOB) are Rs -- and Rs -- as of 05-Apr-2026.
Enochian Biosciences Inc (ENOB) has a market capitalisation of $ 31 Mln as on 23-Jun-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Enochian Biosciences Inc (ENOB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.86
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.